ARIIZUMI Shunichi
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Associate Professor
Article types Original article
Language English
Peer review Non peer reviewed
Title Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study.
Journal Formal name：International journal of cancer
Abbreviation：Int J Cancer
ISSN code：10970215/00207136
Domestic / ForeginForegin
Volume, Issue, Page 147(9),pp.2578-2586
Author and coauthor Okada Rei, Otsuka Yuichiro, Wakabayashi Taiga, Shinoda Masahiro, Aoki Takeshi, Murakami Masahiko, Arizumi Shunichi, Yamamoto Masakazu, Aramaki Osamu, Takayama Tadatoshi, Wakiyama Shigeki, Yanaga Katsuhiko, Amikura Katsumi, Kaneko Hironori, Shimada Hideaki
Publication date 2020/11
Summary Serum autoantibodies have been reported to react with tumor-associated antigen (TAA) in various cancers. This multicenter study evaluated the diagnostic and prognostic value of six autoantibodies against a panel of six hepatocellular carcinoma (HCC)-associated antigens, including Sui1, p62, RalA, p53, NY-ESO-1 and c-myc. A total of 160 patients with HCC and 74 healthy controls were prospectively enrolled from six institutions. Serum antibody titers were determined by enzyme-linked immunosorbent assays. The sensitivities were 19% for Sui1, 18% for p62, 17% for RalA, 11% for p53, 10% for NY-ESO-1 and 9% for c-myc. Overall sensitivity of the TAA panel (56%) was higher than that of α-fetoprotein (41%, P < .05). The combined sensitivity of the TAA panel and α-fetoprotein was significantly higher than that of α-fetoprotein alone (P < .001). The difference in overall survival of TAA panel-positive and panel-negative patients was significant when the Stage I/II patients were combined (P = .023). Overall survival was worse in NY-ESO-1 antibody-positive than in NY-ESO-1 antibody-negative patients (P = .002). Multivariate analysis found that positivity for the TAA panel was independently associated with poor prognosis (P = .030). This TAA panel may have diagnostic and prognostic value in the patients with HCC.
DOI 10.1002/ijc.33165
PMID 32574375